<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum>http://feeds2.feedburner.com/AmericanBankingNews</forum>
<forum_title>American Banking News</forum_title>
<discussion_title>Celgene Co. (CELG) Receives “Buy” Rating from Bank of America</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.americanbankingnews.com/2016/04/25/celgene-co-celg-receives-buy-rating-from-bank-of-america/</topic_url>
<topic_text>
Tweet 
Celgene Co. (NASDAQ:CELG) ‘s stock had its “buy” rating reissued by equities research analysts at Bank of America in a research note issued to investors on Monday, Analyst Ratings Network.com reports. 
Celgene ( NASDAQ:CELG ) traded down 0.24% during trading on Monday, reaching $110.26. 1,812,143 shares of the company’s stock traded hands. Celgene has a 1-year low of $92.98 and a 1-year high of $140.72. The stock has a market capitalization of $86.19 billion and a P/E ratio of 56.84. The stock has a 50-day moving average price of $102.98 and a 200 day moving average price of $108.97. 
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, January 28th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.22 by $0.04. The company had revenue of $2.54 billion for the quarter, compared to analyst estimates of $2.54 billion. During the same period in the prior year, the business earned $1.01 EPS. The firm’s quarterly revenue was up 22.9% compared to the same quarter last year. Equities research analysts expect that Celgene will post $5.69 earnings per share for the current year. 
In other Celgene news, Director James J. Loughlin sold 2,100 shares of the company’s stock in a transaction dated Monday, February 22nd. The stock was sold at an average price of $104.12, for a total value of $218,652.00. Following the completion of the sale, the director now owns 19,785 shares in the company, valued at $2,060,014.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link . Also, Director Gilla Kaplan sold 15,967 shares of the company’s stock in a transaction dated Monday, April 4th. The stock was sold at an average price of $101.84, for a total value of $1,626,079.28. Following the completion of the sale, the director now owns 72,518 shares of the company’s stock, valued at approximately $7,385,233.12. The disclosure for this sale can be found here . 
A number of hedge funds recently modified their holdings of the company. Beacon Capital Management bought a new stake in shares of Celgene during the fourth quarter worth approximately $0. Capital Investment Services of America acquired a new position in Celgene during the fourth quarter worth $207,000. Capital Asset Advisory Services LLC acquired a new position in Celgene during the first quarter worth $303,000. Benjamin F. Edwards &amp; Company Inc. raised its position in Celgene by 8.0% in the first quarter. Benjamin F. Edwards &amp; Company Inc. now owns 3,101 shares of the biopharmaceutical company’s stock worth $310,000 after buying an additional 229 shares during the period. Finally, Diversified Trust Co acquired a new position in Celgene during the fourth quarter worth $320,000. 
CELG has been the subject of a number of other research reports. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $133.83 target price for the company in a research report on Tuesday, December 29th. Canaccord Genuity restated a “buy” rating on shares of Celgene in a research report on Wednesday, December 30th. Wells Fargo restated an “outperform” rating on shares of Celgene in a research report on Friday, January 22nd. Zacks Investment Research upgraded shares of Celgene from a “hold” rating to a “strong-buy” rating and set a $116.00 price objective for the company in a research report on Thursday, January 14th. Finally, Cowen and Company restated an “outperform” rating and issued a $150.00 price objective on shares of Celgene in a research report on Tuesday, April 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, twenty-two have given a buy rating and three have given a strong buy rating to the company’s stock. Celgene has a consensus rating of “Buy” and an average price target of $141.91. 
Celgene Corporation ( NASDAQ:CELG ), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.  //www.americanbankingnews.com/2016/04/25/celgene-co-celg-receives-buy-rating-from-bank-of-america/   Celgene Co.   Celgene Co.  
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.americanbankingnews.com/2016/04/25/celgene-co-celg-receives-buy-rating-from-bank-of-america/</post_url>
<post_date>20160425</post_date>
<post_time>1838</post_time>
<username>ABMN Staff</username>
<post>
Tweet 
Celgene Co. (NASDAQ:CELG) ‘s stock had its “buy” rating reissued by equities research analysts at Bank of America in a research note issued to investors on Monday, Analyst Ratings Network.com reports. 
Celgene ( NASDAQ:CELG ) traded down 0.24% during trading on Monday, reaching $110.26. 1,812,143 shares of the company’s stock traded hands. Celgene has a 1-year low of $92.98 and a 1-year high of $140.72. The stock has a market capitalization of $86.19 billion and a P/E ratio of 56.84. The stock has a 50-day moving average price of $102.98 and a 200 day moving average price of $108.97. 
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, January 28th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.22 by $0.04. The company had revenue of $2.54 billion for the quarter, compared to analyst estimates of $2.54 billion. During the same period in the prior year, the business earned $1.01 EPS. The firm’s quarterly revenue was up 22.9% compared to the same quarter last year. Equities research analysts expect that Celgene will post $5.69 earnings per share for the current year. 
In other Celgene news, Director James J. Loughlin sold 2,100 shares of the company’s stock in a transaction dated Monday, February 22nd. The stock was sold at an average price of $104.12, for a total value of $218,652.00. Following the completion of the sale, the director now owns 19,785 shares in the company, valued at $2,060,014.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link . Also, Director Gilla Kaplan sold 15,967 shares of the company’s stock in a transaction dated Monday, April 4th. The stock was sold at an average price of $101.84, for a total value of $1,626,079.28. Following the completion of the sale, the director now owns 72,518 shares of the company’s stock, valued at approximately $7,385,233.12. The disclosure for this sale can be found here . 
A number of hedge funds recently modified their holdings of the company. Beacon Capital Management bought a new stake in shares of Celgene during the fourth quarter worth approximately $0. Capital Investment Services of America acquired a new position in Celgene during the fourth quarter worth $207,000. Capital Asset Advisory Services LLC acquired a new position in Celgene during the first quarter worth $303,000. Benjamin F. Edwards &amp; Company Inc. raised its position in Celgene by 8.0% in the first quarter. Benjamin F. Edwards &amp; Company Inc. now owns 3,101 shares of the biopharmaceutical company’s stock worth $310,000 after buying an additional 229 shares during the period. Finally, Diversified Trust Co acquired a new position in Celgene during the fourth quarter worth $320,000. 
CELG has been the subject of a number of other research reports. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $133.83 target price for the company in a research report on Tuesday, December 29th. Canaccord Genuity restated a “buy” rating on shares of Celgene in a research report on Wednesday, December 30th. Wells Fargo restated an “outperform” rating on shares of Celgene in a research report on Friday, January 22nd. Zacks Investment Research upgraded shares of Celgene from a “hold” rating to a “strong-buy” rating and set a $116.00 price objective for the company in a research report on Thursday, January 14th. Finally, Cowen and Company restated an “outperform” rating and issued a $150.00 price objective on shares of Celgene in a research report on Tuesday, April 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, twenty-two have given a buy rating and three have given a strong buy rating to the company’s stock. Celgene has a consensus rating of “Buy” and an average price target of $141.91. 
Celgene Corporation ( NASDAQ:CELG ), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.  //www.americanbankingnews.com/2016/04/25/celgene-co-celg-receives-buy-rating-from-bank-of-america/   Celgene Co.   Celgene Co.  
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image>http://www.americanbankingnews.com/logos/Celgene%20logo.jpg</main_image>
</document>
